CA3251624A1 - SALINE AND CRYSTALLINE FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR - Google Patents

SALINE AND CRYSTALLINE FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR

Info

Publication number
CA3251624A1
CA3251624A1 CA3251624A CA3251624A CA3251624A1 CA 3251624 A1 CA3251624 A1 CA 3251624A1 CA 3251624 A CA3251624 A CA 3251624A CA 3251624 A CA3251624 A CA 3251624A CA 3251624 A1 CA3251624 A1 CA 3251624A1
Authority
CA
Canada
Prior art keywords
egfr
mesylate salt
powder diffraction
diffraction pattern
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3251624A
Other languages
English (en)
French (fr)
Inventor
Eric Gruff
Shanming Kuang
Anjali Pandey
Harsh Shah
Tian XIE
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CA3251624A1 publication Critical patent/CA3251624A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3251624A 2022-05-04 2023-05-04 SALINE AND CRYSTALLINE FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR Pending CA3251624A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
US63/338,371 2022-05-04
PCT/US2023/020925 WO2023215431A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
CA3251624A1 true CA3251624A1 (en) 2023-11-09

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3251624A Pending CA3251624A1 (en) 2022-05-04 2023-05-04 SALINE AND CRYSTALLINE FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR

Country Status (12)

Country Link
US (1) US20250282761A1 (enExample)
EP (1) EP4519254A1 (enExample)
JP (1) JP2025517634A (enExample)
KR (1) KR20250012078A (enExample)
CN (1) CN119923392A (enExample)
AU (1) AU2023265064A1 (enExample)
CA (1) CA3251624A1 (enExample)
IL (1) IL316663A (enExample)
MX (1) MX2024013485A (enExample)
TW (1) TW202409016A (enExample)
UY (1) UY40256A (enExample)
WO (1) WO2023215431A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097270A1 (en) * 2022-11-01 2024-05-10 Blueprint Medicines Corporation Egfr inhibitors for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
IL302457A (en) * 2020-10-30 2023-06-01 Blueprint Medicines Corp Pyrimidine compounds, preparations and their medical applications
CA3196857A1 (en) * 2020-10-30 2022-05-05 Gurulingappa Hallur Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
TW202409016A (zh) 2024-03-01
AU2023265064A1 (en) 2024-11-14
US20250282761A1 (en) 2025-09-11
MX2024013485A (es) 2024-12-06
IL316663A (en) 2024-12-01
WO2023215431A1 (en) 2023-11-09
EP4519254A1 (en) 2025-03-12
JP2025517634A (ja) 2025-06-10
CN119923392A (zh) 2025-05-02
KR20250012078A (ko) 2025-01-23
UY40256A (es) 2023-11-15

Similar Documents

Publication Publication Date Title
TWI884890B (zh) (s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途
US9630952B2 (en) Crystalline forms of afatinib di-maleate
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
US9879008B2 (en) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
CN115461341A (zh) 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的晶型
US20210388000A1 (en) Crystalline forms of lorlatinib maleate
CN114867531B (zh) Egfr抑制剂
JP7775186B2 (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
US10640487B2 (en) Solid state forms of Nilotinib salts
CN121889396A (zh) 用于治疗甲状腺眼病的林西替尼的结晶盐
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
CN112424187B (zh) 抑制jak的化合物的昔萘酸盐
US11878980B2 (en) Solid forms of TTK inhibitor
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
KR20250038235A (ko) 고체 형태의 jak 억제제 및 이의 제조 공정
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
CN102666528B (zh) 晶体cdc7 抑制剂盐
TW202102487A (zh) N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途
WO2025247352A1 (zh) 化合物的晶型、盐型、溶剂合物、水合物及其用途
TW202416984A (zh) 化合物i或其鹽的固體形式
JP2025525475A (ja) Ｎ－［４－（４－［［２－（ジメチルアミノ）エチル］アミノ］－３－メチル－１Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－６－イル）－２－フルオロフェニル］－２，５－ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態
HK40099156A (zh) 经取代的吡唑并嘧啶的固态形式和其用途
HK40117473A (zh) 活化素受体样激酶抑制剂的盐和晶体形式
HK1260821B (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241101

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241101

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250131

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250131

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401